FDA approves Leqembi (lecanemab) for monthly maintenance dosing for early Alzheimer’s disease – Eisai
The FDA has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease. The decision follows a supplemental application from Eisai, which is codeveloping Leqembi… read more.